Novartis Plans to Move Infectious Disease Research Group to the Bay Area
This article was originally published in The Pink Sheet Daily
Executive Summary
The company has hired a high-profile professor with a nose for virus sleuthing as its new ID chief, and it will start shifting its 120-member R&D staff from the Boston area next year.
You may also be interested in...
Idenix Clinical Hold On Two Hep C Programs May Be Resolved By Year-End
Phase I study combining two of the biotech's drugs reveals liver problems.
Novartis Buys into New Pharma World Order
In paying $5.1 billion for vaccine maker Chiron, Novartis is pursuing a unique business strategy which recognizes the growing role of governments, both as purchasers and as price-setters. The same strategy assumes, too, that pharma must seek alternative growth sources to branded prescription drugs.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.